News

NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies | DelveInsight
In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab ...
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies | DelveInsight
DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2025” report provides comprehensive insights about 80+ ...
BioSpace2d
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...
Alzheimer's Disease Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
DelveInsight's Alzheimer's Disease Pipeline report depicts a robust space with 200+ active players working to develop 220+ ...
Chronic Kidney Disease Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...
Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal
Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...
Purdue University1mon
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
INDIANAPOLIS and WEST LAFAYETTE, May 9, 2025 — Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly’s planned ...
Finanznachrichten1mon
Eli Lilly and Company: Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 9, 2025 /PRNewswire/ -- Eli Lilly and Company ... of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.